Rhythm Pharmaceuticals (RYTM) Tops Q3 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq set for higher open as oil prices extend declines, midterm results awaited
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts RYTM Hot Sheet
Join SI Premium – FREE
Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q3 EPS of ($0.61), $0.10 better than the analyst estimate of ($0.71). Revenue for the quarter came in at $92.1 million versus the consensus estimate of $85.44 million.
For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Iran Rejects Reports Its Close To A Deal With US - IRIB
- Increasing unusual call option volume: WMB XFOR UPWK SGHC INO ROKU EDV SRE BKR CSX GTM LSCC
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
